| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | GSK1605786 fka Traficet-EN, fka CCX282-B | |
| 3 | Economics | ChemoCentryx option exercised 1/11/10. Worldwide commercialization by GSK, with DD% royalties to ChemoCentryx. | |
| 4 | Indication | Crohn's Disease | |
| 5 | Mechanism | CCR9 antagonist small molecule | |
| 6 | Clinical Trials | ||
| 7 | Phase III Induction study versus placebo | ||
| 8 | |||
| 9 | |||
| 10 | Phase II PROTECT-1 |